Summary of Invention
Genetic profiling of tumors is an effective approach to cancer treatment. There is an unmet need in this field to better understand the genetic profile of different classes of tumors in an effort to tailor the therapy to suit individual needs.
The present invention provides identification of a gene expression profile that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway. This technology could be used for qualifying the cancer status and response in patients, for monitoring the efficacy of a chemotherapeutic regimen and for screening new compounds
Advantages
- Excellent prognostic indicator in improving patient outcomes
- Sensitive detection of anti-tumor response
- Potential to tailor individual treatment regimen
- Screening tool for new compounds
- Novel therapeutic targets
Areas of Application
Therapeutic, prognostic, and research tool
Lead Inventors
Neal Rosen, MD, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering
Patent Information
U.S. patent issued: 7,812,143
References
- Presented at the AACR meeting ( March 31st, 2006)
- Pratilas CA, et al. (2008) Cancer Res; 68(22):9375-83
- Pratilas CA, et al. (2009) Proc Natl Acad Sci U S A; 106(11):4519-24